Published in
Elsevier, European Journal of Cancer, (155), p. 294-295, 2021
DOI: 10.1016/j.ejca.2021.07.005
Links
Tools
Re: Post-progression outcomes of NSCLC patients with PD-L1 expression ≥50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 